L&T Finance Q1 Results: Net profit rises 10% QoQ to Rs 701 crore, retail book up 18% YoY
Retail disbursements stood at ₹17,522 crore for the quarter, up 18% from last year, led by growth in Farmer Finance, Home Loans, LAP, and Gold Loans. On the unsecured side, Personal Loans continued to gain traction.
Retailisation reached 98%, surpassing LTF's Lakshya 2026 target. Meanwhile, the company successfully integrated its recently acquired Gold Loan portfolio and launched 'Project Cyclops' for SME Finance.
Asset quality remained stable with Gross Stage 3 at 3.31% and Net Stage 3 at 0.99%. Credit cost dropped to 2.23%, even after provisioning ₹300 crore in Rural Business Finance. Return on Assets improved to 2.37% from 2.22% in the previous quarter.
The company also saw a 16 bps sequential drop in the Weighted Average Cost of Borrowing to 7.68%. Net Interest Margin plus fees came in at 10.22%, while Return on Equity stood at 10.86%.
With strong digital capabilities and a diversified retail portfolio, L&T Finance continues to build a resilient, high-quality consumer lending franchise in line with its Lakshya 2026 vision.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
L&T Technology Services signs $60 million multi-year agreement with leading US telecom firm
L&T Technology Services (LTTS) has announced a major win in the tech space by signing a multi-year deal worth around $60 million with a top U.S.-based wireless telecom provider. This new partnership strengthens LTTS' already decade-long relationship with the client and marks a big step forward in its network software development and engineering services portfolio. As part of the agreement, LTTS will offer advanced engineering services, including R&D lab integration, new product development, and functionality testing for the client's network software automation platforms. To make delivery even more seamless, LTTS plans to set up a dedicated delivery center in the U.S. This engagement highlights LTTS' deep expertise in next-gen network solutions and its growing capabilities in Smart World Connectivity. It also builds on the company's long-standing investments in high-tech labs, customized solutions, and nearshore centers—all of which played a big role in landing this deal. Looking ahead, LTTS aims to expand its service offerings for the client by introducing AI-powered test automation platforms. This move is expected to accelerate product development and boost overall efficiency for the telecom provider. Amit Chadha, CEO and Managing Director, L&T Technology Services, commented on the development, saying, 'This new agreement in our Tech segment with such a prestigious Telecommunications leader reinforces our longstanding relationship and shared vision in nextgeneration communications, network automation, and AI. By leveraging our Smart World connectivity solutions along with our extensive expertise in enterprise 5G rollouts and telecom innovations, we are proud to contribute toward achieving the client's strategic goals.' Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
a day ago
- Business Upturn
Nibe signs Technical Collaboration Agreement with Israel's Elbit Systems for PULS rocket system
Nibe Limited has officially entered into a technical collaboration agreement with Israel-based defence technology firm Elbit Systems Land Limited. Signed on July 26, 2025, the agreement focuses on the transfer of license and technology for the Precise & Universal Launch System (PULS), a high-range artillery rocket system. Under this agreement, Elbit will provide Nibe with the necessary know-how and licensing rights to manufacture and assemble the PULS system in India. The system is designed for long-range precision targeting, capable of engaging threats at distances up to 300 kilometers. The collaboration aims to establish a local manufacturing setup for PULS in India, allowing Nibe to take on responsibilities for development, assembly, and integration. The financial terms of the agreement are expected to be finalized within 45 days from the signing date. This is a purely international partnership between two independent entities, with no related party transaction involved. Neither Nibe's promoter group nor its affiliates have any stake or interest in Elbit Systems Land Limited. The agreement aligns with the regulatory requirements under SEBI's disclosure norms. With this development, Nibe Limited expands its presence in the defence manufacturing sector by bringing advanced rocket system capabilities to the domestic market through technology collaboration with a global player. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 days ago
- Business Upturn
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. These tablets are the generic version of Tegretol-XR, a widely used anticonvulsant drug developed by Novartis Pharmaceuticals. Alembic's version is therapeutically equivalent to the original, meaning it meets the same standards for quality, strength, and effectiveness. Carbamazepine Extended-Release Tablets are primarily used to treat seizure disorders and are also prescribed for trigeminal neuralgia, a chronic pain condition affecting the facial nerves. According to IQVIA data, the US market for this drug was valued at approximately $71 million for the 12-month period ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, which includes 202 final approvals and 23 tentative approvals. About Alembic Pharmaceuticals Founded in 1907 and headquartered in India, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company known for its strong focus on research and development. It manufactures and markets generic drugs across global markets, with several of its facilities approved by top regulatory bodies including the USFDA. In India, Alembic is a leader in branded generics, with a product portfolio promoted by a field force of over 5,500 professionals. Its products are widely recognized and trusted by healthcare professionals and patients alike. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
